We are live on !
Find out more
Enavate Sciences Portfolio holdings
AUM
$345M
Turnover
0%
1-Year Est. Return
134.64%
This Quarter Est. Return
+57.34%
1 Year Est. Return
+134.64%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$507M
AUM Growth
+$179M
(+55%)
Cap. Flow
+$2M
Cap. Flow % of AUM
Cap. Flow %
0.39%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
1
Reduced
1
Closed
–
Avg Time Held
0.9
years
Top 10 Avg Time Held
0.9
years
Top 20 Avg Time Held
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zenas BioPharma
ZBIO
|
+$5.19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CAMP4 Therapeutics
CAMP
|
+$3.19M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Zenas BioPharma
ZBIO
$1.85B
| $142M | 28.08% |
3,919,159
+157,800
| +4% | +$5.19M |
2024 Q4
4 quarters
|
|
2
Immunome
IMNM
$2.15B
| $102M | 20.21% |
4,768,583
| – | – |
2024 Q4
4 quarters
|
|
3
Sionna Therapeutics
SION
$175M
| $102M | 20.12% |
2,478,030
| – | – |
2025 Q1
3 quarters
|
|
4
Upstream Bio Inc
UPB
$187M
| $66.8M | 13.18% |
2,459,703
| – | – |
2024 Q4
4 quarters
|
|
5
Compass Therapeutics
CMPX
$142M
| $41.8M | 8.25% |
7,788,150
| – | – |
2024 Q4
4 quarters
|
|
6
BridgeBio Oncology
BBOT
$210M
| $32.9M | 6.49% |
2,626,946
| – | – |
2025 Q3
1 quarter
|
|
|
7
CAMP4 Therapeutics
CAMP
$249M
| $18.6M | 3.67% |
3,035,825
-749,977
| -20% | -$3.19M |
2024 Q4
4 quarters
|
|
Similar funds
LCM
WFI
Enavate Sciences's Q4 2025 Portfolio in Review
As of Q4 2025, Enavate Sciences held 7 positions worth $507M, up 55% from $328M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Trading was light in Q4 2025: portfolio turnover was 0%. Enavate Sciences opened no new positions and made no exits, leaving the 7-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Enavate Sciences added most to Zenas BioPharma in Q4 2025, an estimated $5.19M increase.
- Enavate Sciences's biggest Q4 2025 reduction was CAMP4 Therapeutics, cutting an estimated $3.19M.
- Enavate Sciences's ten largest holdings make up 100% of its $507M portfolio in Q4 2025.
- Enavate Sciences opened 0 new positions and closed 0 in Q4 2025.
- Enavate Sciences's portfolio value rose 55% quarter-over-quarter to $507M.
Based on Enavate Sciences's 13F filing for Q4 2025, filed 17 Feb 2026.